XML 21 R8.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Consolidated Statements of Cash Flows - USD ($)
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Cash flows from operating activities      
Net loss $ (235,329,000) $ (90,733,000) $ (159,457,000)
Adjustments to reconcile net loss to cash from operating activities      
Derecognition of the TRA liability 0 0 (122,515,000)
Depreciation and amortization 92,800,000 111,292,000 122,102,000
Equity-based compensation expense 11,280,000 10,621,000 13,825,000
Goodwill impairment 111,108,000 0 0
Loss on asset impairments and retirements 40,686,000 0 71,942,000
Amortization of deferred financing costs 371,000 58,000 267,000
Deferred tax provision (benefit) 727,000 (14,634,000) 15,543,000
Reversal of deferred tax assets associated with the TRA 0 0 46,874,000
Provision for bad debts 1,281,000 159,000 950,000
(Gain) loss on disposal of assets 1,037,000 (1,309,000) (2,045,000)
Changes in fair value of investments (2,747,000) 1,199,000 (2,627,000)
Unrealized (gain) loss on derivative instruments 222,000 (386,000) 634,000
Realized loss on sale of investment 0 0 478,000
Other (1,522,000) 843,000 (1,876,000)
Changes in operating assets and liabilities, net of effects from acquisitions      
Accounts receivable 22,152,000 (63,654,000) 21,271,000
Inventories (10,694,000) (2,917,000) 12,102,000
Other current assets 856,000 4,581,000 8,677,000
Other assets (1,285,000) 258,000 674,000
Accounts payable and accrued liabilities (3,937,000) 15,310,000 15,774,000
Deferred revenue 545,000 (354,000) (13,373,000)
Other noncurrent liabilities (503,000) (2,978,000) (4,446,000)
Net cash provided by (used in) operating activities 27,048,000 (32,644,000) 24,774,000
Cash flows from investing activities      
Purchase of property, plant and equipment and intangibles (36,942,000) (19,734,000) (21,990,000)
Purchase of property, plant and equipment from related parties 0 (36,737,000) 0
Proceeds from sale of assets and equipment 791,000 7,089,000 14,030,000
Purchase of investments (20,122,000) (84,040,000) (123,048,000)
Proceeds from sale of investments 46,739,000 143,825,000 53,299,000
Other (512,000) 0 0
Net cash provided by (used in) investing activities (10,046,000) 10,403,000 (77,709,000)
Cash flows from financing activities      
Repayments of borrowings (5,627,000) (5,892,000) (680,000)
Dividends paid on common stock 0 0 (50,154,000)
Deferred financing costs (184,000) (1,733,000) 0
Treasury shares withheld (1,886,000) (1,636,000) (2,901,000)
Proceeds from the issuance of ESPP shares 1,752,000 1,315,000 1,264,000
Net cash used in financing activities (5,945,000) (7,946,000) (52,471,000)
Effect of exchange rate changes on cash (529,000) 3,384,000 (1,105,000)
Net increase (decrease) in cash, cash equivalents and restricted cash 10,528,000 (26,803,000) (106,511,000)
Cash, cash equivalents and restricted cash at beginning of period 186,212,000 213,015,000 319,526,000
Cash, cash equivalents and restricted cash at end of period $ 196,740,000 $ 186,212,000 $ 213,015,000